Chugai’s Lasker award-winning Hemlibra developers outlined efforts to make the company’s next-generation hemophilia A bispecific obsolete. The program centers on NXT007, designed to increase factor VIII-mimetic activity above 40% of low-normal clotting function, roughly double Hemlibra emicizumab’s cited activity level. The approach underscores how competitive pressures in hemophilia are increasingly focused on pushing potency higher and refining performance attributes that matter for patients and treatment economics. Chugai framed the development as an attempt to sustain leadership as new bispecifics and alternative mechanisms emerge.